← Back to All Filings

Moderna CFO James M. Mock Reports Routine RSU Vesting and Tax Withholding

Low SignificanceAugust 31, 2026 at 5:11:35 PM EDT

Moderna, Inc.

$MRNA4CIK: 0001682852

Subscribe to track MRNA

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Moderna, Inc. ($MRNA) Form 4 Filing Summary

Insider: James M Mock (Chief Financial Officer) Filing Date: August 31, 2026 Transaction Date: August 27–28, 2026

Transaction Overview:

  • Acquisitions (RSU Vesting): 1,103 shares acquired via RSU conversion (774 shares on 08/27, 329 shares on 08/28) at $0.00.
  • Dispositions (Tax Withholding): 535 shares withheld for taxes (375 shares at $149.66, 160 shares at $142.77) for a total value of ~$78,965.70.
  • Ending Direct Holdings: 67,004 shares of Common Stock.

Significance: Low — Standard equity vesting and automated tax withholding.

Comprehensive Analysis

Executive Summary

On August 31, 2026, Moderna, Inc. ($MRNA) Chief Financial Officer James M. Mock filed a Form 4 disclosing routine equity award vesting and associated tax withholding transactions that occurred on August 27 and August 28, 2026.

Transaction Details

  • August 27, 2026:
    • Acquired 774 shares of Common Stock upon the vesting of Restricted Stock Units (RSUs) (Code M).
    • Disposed of 375 shares at $149.66 per share to cover statutory tax withholding obligations (Code F), valued at $56,122.50.
  • August 28, 2026:
    • Acquired 329 shares of Common Stock upon RSU vesting (Code M).
    • Disposed of 160 shares at $142.77 per share to satisfy tax withholding obligations (Code F), valued at $22,843.20.

Post-Transaction Holdings

Following these transactions, James M. Mock directly beneficially owns 67,004 shares of Moderna Common Stock, alongside remaining unvested RSU balances.

Significance Assessment

  • Significance Level: Low
  • Context: The transactions reflect scheduled quarterly vesting of previously granted RSU awards and the mandatory disposition of shares to cover tax obligations. There were no discretionary open-market sales or purchases.
Topics:#Moderna#MRNA#InsiderTrading#Form4#Biotech

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.